Narsoplimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Narsoplimab. Educational only — not medical advice.
Labeled uses
YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Source: FDA labeling via NIH DailyMed (set f8ff990a…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.